Northland Securities analyst Suraj Kalia maintained a Hold rating on Dexcom Inc (DXCM) today and set a price target of $125. The company’s shares opened today at $123.03.
Kalia commented:
“We present here a comparative assessment of 2.0 data readouts. Our global view is….we love Dexcom, but believe the story is going to be pressured on all fronts….top-line growth, margins, and market share. If this data is representative of the FDA submission (or part thereof), there is no doubt that Libre 2.0 will get an “i” designation.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 11.1% and a 60.7% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom Inc with a $161.71 average price target.
See today’s analyst top recommended stocks >>
Based on Dexcom Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $26.9 million. In comparison, last year the company had a GAAP net loss of $24.2 million.
Based on the recent corporate insider activity of 126 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DXCM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share,and Mobile apps.
